ALCLS Cellectis SA

Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market.

The publication will be followed by an investor conference call and webcast on Friday, March 14, 2025, at 8:00 AM ET / 1:00 PM CET. The call will include the Company’s fourth quarter and full year 2024 results and an update on business activities. Details for the call are as follows:

Dial in information:

Domestic:

International:

Conference ID: CLLS24

Webcast Link:

About Cellectis     

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit and follow Cellectis on and .

TALEN® is a registered trademark owned by Cellectis. 

For further information on Cellectis, please contact:     

Media contacts:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:       

Arthur Stril, Chief Financial Officer & Chief Business Officer,        

Attachment



EN
07/03/2025

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

Julian Dobrovolschi
  • Julian Dobrovolschi
ENX EURONEXT NV
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
ALLIX WALLIX GROUP SA
DB1 DEUTSCHE BOERSE AG
AAL ANGLO AMERICAN PLC
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
MF WENDEL SE
LSEG LONDON STOCK EXCHANGE GROUP PLC
LEI LEIFHEIT AG
SZG SALZGITTER AG
GXI GERRESHEIMER AG
EKI EKINOPS SA
RF EURAZEO SA
ALCLS CELLECTIS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
A1XA4J CARBIOS SA
ERA ERAMET SA
POS PORR AG
ROS ROSENBAUER INTERNATIONAL AG
NDA AURUBIS AG
KRN KRONES AG
PAT PATRIZIA AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
TKO TIKEHAU CAPITAL SCA
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
ANTIN ANTIN INFRASTRUCTURE PARTNERS
ALLFG ALLFUNDS (UK) LTD
FLOW FLOW TRADERS LTD
SCHOTT PHARMA AG
CVC CVC CAPITAL PARTNERS PLC
HAVAS HAVAS N.V
04/11/25 April 11, 2025 1 EN
Julian Dobrovolschi
  • Julian Dobrovolschi
ENX EURONEXT NV
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
ALLIX WALLIX GROUP SA
DB1 DEUTSCHE BOERSE AG
AAL ANGLO AMERICAN PLC
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
MF WENDEL SE
LSEG LONDON STOCK EXCHANGE GROUP PLC
LEI LEIFHEIT AG
SZG SALZGITTER AG
GXI GERRESHEIMER AG
EKI EKINOPS SA
RF EURAZEO SA
ALCLS CELLECTIS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
A1XA4J CARBIOS SA
ERA ERAMET SA
POS PORR AG
ROS ROSENBAUER INTERNATIONAL AG
NDA AURUBIS AG
KRN KRONES AG
PAT PATRIZIA AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
TKO TIKEHAU CAPITAL SCA
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
ANTIN ANTIN INFRASTRUCTURE PARTNERS
ALLFG ALLFUNDS (UK) LTD
FLOW FLOW TRADERS LTD
SCHOTT PHARMA AG
CVC CVC CAPITAL PARTNERS PLC
HAVAS HAVAS N.V
04/11/25 April 11, 2025 1 FR
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
ALCLS CELLECTIS SA

Cellectis : Cellectis: the reference player in allogeneic CAR-T cells

Cellectis is the French specialist in allogeneic CAR-T cells, now mainly developed in cancer treatment. Its first CAR-T in partnership with Servier and Allogene is currently in the pivot phase in first-line diffuse B-cell lymphoma, while its most advanced own CAR-T candidate is expected to enter into the pivot phase II in H2 this year in acute lymphoblastic leukaemia. Bolstered by a recent deal with AstraZeneca, which acquired a stake in the company (+44%), we are initiating coverage of the stoc...

04/10/25 April 10, 2025 1 EN
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
ALCLS CELLECTIS SA

Cellectis : Cellectis : l’acteur de référence des CAR-T allogéniques

Cellectis est le spécialiste français des CAR-T allogéniques, développés aujourd’hui essentiellement dans le traitement des cancers. Son premier CAR-T partenarisé à Servier et Allogene est actuellement en phase pivot en 1ere L du lymphome diffus à cellules B alors que son candidat CAR-T propre le plus avancé devrait entrer en phase 2 pivot au S2 de cette année en Leucémie Lymphoïde Aigue. Fort d’un accord récent avec AstraZeneca qui a pris une participation dans la société (44%), nous initions l...

04/10/25 April 10, 2025 1 FR
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, April 07, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights03/31/2025100,290,07889,046,759 For further information on Cellectis, please contact:      Media contacts:        Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations co...

April 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch